Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Martinez

Pulmonary Disease Deerfield Beach, FL Medical Doctor

NPI 1417191891 CMS profile 336302

1 W Sample Rd Ste 304, Deerfield Beach, FL 33064

Open in the dashboard

General payments

$11,352

488 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Martinez of Deerfield Beach, FL is reported in the CMS Open Payments database as having received $11,352 across 488 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,826 80
2024 General $2,203 55
2023 General $1,411 66
2022 General $1,337 69
2021 General $1,666 71
2020 General $1,351 66
2019 General $1,559 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Martinez
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jose Martinez were reported at $1,826. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jose Martinez Pulmonary Disease median Middle half National median
2019 $1,559 $377 $109–$1,340 $163
2020 $1,351 $230 $56–$907 $114
2021 $1,666 $269 $68–$1,072 $132
2022 $1,337 $390 $100–$1,457 $149
2023 $1,411 $419 $114–$1,659 $160
2024 $2,203 $476 $123–$1,818 $164
2025 $1,826 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,630 136 payments
  2. GlaxoSmithKline, LLC. $1,885 96 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,633 77 payments
  4. Inari Medical, Inc. $1,388 7 payments
  5. Insmed, Inc. $288 17 payments
  6. Viatris Specialty LLC $278 10 payments
  7. Mylan Specialty L.P. $271 11 payments
  8. Genzyme Corporation $268 11 payments
  9. Regeneron Healthcare Solutions, Inc. $244 11 payments
  10. Amgen Inc. $197 9 payments
  11. Other $2,270 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,674 475 payments
  2. Travel and Lodging $464 2 payments
  3. Education $215 11 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $1,759 9 payments
  2. TRELEGY ELLIPTA $1,263 62 payments
  3. CT THROMBECTOMY SYSTEM KIT $1,017 5 payments
  4. BREZTRI $851 45 payments
  5. SYMBICORT $674 36 payments
  6. STIOLTO RESPIMAT Respiratory $604 32 payments
  7. AIRSUPRA $529 26 payments
  8. YUPELRI $480 18 payments
  9. OFEV $478 16 payments
  10. STIOLTO RESPIMAT Respiratory $309 18 payments
  11. Other $4,798 234 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

4,774

Median for Pulmonary Disease: 936

Drug cost

$1,380,667

Median for Pulmonary Disease: $487,987

Branded share of claims

83.2%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 354 $284,339
Opsumit Macitentan Brand 13 $163,703
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 228 $161,061
Spiriva Respimat Tiotropium Bromide Brand 223 $151,692
Breo Ellipta Fluticasone/Vilanterol Brand 196 $102,022
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 182 $101,070
Symbicort Budesonide/Formoterol Fumarate Brand 357 $99,811
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 95 $51,789
Albuterol Sulfate Hfa Albuterol Sulfate Brand 1,290 $39,261
Spiriva Handihaler Tiotropium Bromide Brand 53 $38,888

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$344,606

Medicare's payments for the services billed

Medicare patients

559

Average age 78

Services billed

3,357

276 women, 283 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 58%
Arthritis 54%
Ischemic heart disease 53%
Chronic kidney disease 46%
Heart failure 44%
Depression 43%
Diabetes 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$316 354 —
AIRSUPRA
$260 — —
TEZSPIRE
$124 — —
DUPIXENT
$101 — —
YUPELRI
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record